Loading organizations...
Innolake Biopharm is a clinical-stage biotech company developing innovative medicines for cancer and autoimmune diseases, based in Hangzhou, Zhejiang, China. The company leverages proprietary platforms for small molecules, biologics, and ADCs, cultivating a pipeline of over ten first-in-class and best-in-class candidates, with two currently in clinical stages. It raised $40 million in Pre-Series A funding in March 2021 to support its development efforts, including the A2aR antagonist ILB-2109, which entered Phase 1a trials in April 2022. Innolake Biopharm has garnered industry recognition, appearing on the 2022 China Biopharmaceutical Industry Innovation list and being named a "Top 10 Biopharmaceutical Company with Highest Growth Potential" at BIO-FORUM 2023. The organization was established in 2020 by Dr. Mingde Xia, formerly of Johnson & Johnson, and Mr. Robert Chen, previously with Genor Biopharma.
Innolake Biopharm has raised $108.0M across 1 funding round.
Innolake Biopharm has raised $108.0M in total across 1 funding round.
Innolake Biopharm has raised $108.0M across 1 funding round. Most recently, it raised $108.0M Series B in December 2025.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Dec 10, 2025 | $108M Series B | Temasek | — | Announced |
Innolake Biopharm has raised $108.0M in total across 1 funding round.
Innolake Biopharm's investors include Temasek.
